Semin Liver Dis 2021; 41(03): 277-284
DOI: 10.1055/s-0041-1723030
Review Article

Assessing Toxicity in Drug Trials in Liver Disease

Morris Sherman
1   Research Administration, University Health Network, Toronto, Canada
› Author Affiliations


Since the early trials in viral hepatitis, more and more new drugs are being tested for use in various liver diseases. Since drug hepatotoxicity is a major cause of drugs under investigation not making it to market, the assessment of drug-induced liver injury in clinical trials of new drugs is crucial. This review will focus on the systems that are used to assess drug-induced liver injury in clinical trials and will discuss how some of these criteria are inappropriate or inaccurate in this function together with suggestions for improvement.

Publication History

Article published online:
08 March 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA